Medical
Dr Paul Eliadis
Dr Paul Eliadis practices at Icon Cancer Care with clinics situated throughout Queensland. Dr Eliadis has been and continues to be involved in numerous clinical trials in relation to malignant disease both as principal investigator and sub-investigator. He held the position of Chairman of the HOCA Board (now known as Icon Cancer Care) from 2006 to 2009.
In the specialties of Clinical Haematology and Medical Oncology, Dr Eliadis lists his particular interests as the management of malignant disease and stem cell transplantation. These include malignant Lymphoma, Hodgkin’s Disease, acute and chronic Leukaemias, colorectal cancers, other malignancies of the gastro-intestinal tract, breast cancer, lung cancer, sarcomas, prostate cancer, malignant tumors of the central nervous system and malignancies of the genito-urinary tract. Dr Paul Eliadis works closely with Radiation Oncologists in managing patients with malignant disease who require concurrent chemo-radiotherapy. These include patients with cancer of the head and neck, oesophagus and rectum.
MBBS(Qld) BSc(Med) FRACP FRCPA
Experience
Over the last 20 years, Dr Paul Eliadis has gained vast experience in the management of both Haematological and non-Haematological malignant disease. He is a foundation director of Haematology and Oncology Clinics of Australia. In 1988, he along with Dr Ian Bunce and Dr Trevor Olsen established The Wesley Clinic for Haematology and Oncology. Since then, this clinic has developed into the largest and most progressive provider of haematology and oncology day services in Australia, and is today known as Icon Cancer Care.
Dr Eliadis is committed to ensuring patients with malignant disease receive the highest quality treatment and care within the day hospital setting of Icon Cancer Care.
news
Latest Clinical Trials
As a leader in the fields of Oncology and Haematology in Australia, Dr Paul Eliadis is active across a number of important clinical trials in these fields as both contributor and principal investigator. Catch up on the latest news in clinical trials involving Dr Paul in Haematology and Oncology below.
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK105 as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK105 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK105 as a single agent at the MTD or RP2D.
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK112 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK112 as a single agent at the MTD or RP2D.
Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody
This is a first-in-human, Phase 1, multicenter, open label, single arm, integrated 3-part dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 administered intravenously to adult subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas.
news
Latest News
Catch up on the latest news featuring Dr Paul from all around the web, including his work in Haematology and Oncology, community work and donations, the arts, the Paul Eliadis Foundation and more!
Not if, When
There are 600 million reasons to be proud following the closure of UQ’s first comprehensive campaign, Not if, When – the Campaign to Create Change.
In 2021, Dr Eliadis was awarded a Doctor of Letters honoris causa in recognition of his impact at the University, in the state and in the country, both in his medical career and commitment to the arts .
Australia Day Honours
Dr Eliadis was recognised for significant service to medicine as a clinical haematologist, and to his various charitable initiatives. Browse the full honours list here.